Potentially practice-changing results have come out of an international study on how clinicians can reduce the risk of disease returning for kidney cancer patients. A trial demonstrates that taking oral tablet Sunitinib for one year reduces the likelihood of cancer returning for kidney cancer patients following removal of the kidney.